Q-omics provides the consensus-scored PDE7A profile across patient tissues and cancer cell-line models. PDE7A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PDE7A is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, PDE7A RNA expression shows 19,275 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, HNSC, and UVM as cancer lineages where PDE7A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE7A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE7A survival associations across molecular data types. PDE7A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE7A RNA expression–survival associations across cancer types. High PDE7A expression shows unfavorable associations in LIHC, UVM, MESO, LUSC and KIRP, but favorable associations in SKCM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for PDE7A RNA expression.
This table summarizes PDE7A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PDE7A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE7A shows higher tumor expression in HNSC, KIRC, STAD, LIHC, BLCA and KIRP. The HNSC box plot shows higher PDE7A RNA expression in tumor versus normal tissue (log2 FC = +1.900, t-test p < 0.001).
This table shows molecular features associated with PDE7A in patient tissues and cancer cell lines. In patient samples, PDE7A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE7A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
